High prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium

Journal of Carcinogenesis

Volumn 7, Issue , 2008, Pages

  Al Dujaily, Esraa ^a   Al Janabi, Asad ^a   Pierscionek, Tomasz ^b   Yasseen, Akeel ^a,c  

^a UNIVERSITY OF KUFA   (Iraq)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Breast cancer; gene overexpression; HER 2 neu receptor; immunohistochemistry

Indexed keywords

BIOLOGICAL MARKER; BIOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; PARAFFIN; STREPTAVIDIN; URANIUM;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRAQ; MAJOR CLINICAL STUDY; PREVALENCE; PROTEIN EXPRESSION; TISSUE SECTION; TUMOR VOLUME;

EID: 64149119991     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.44026     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;21:3651-64.
3. Hung MC, Lau YK. Basic science of HER-2/neu: A review. Semin Oncol 1999;26:51-9.
4. Coussens L, Yang-Feng TL, Lioa YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
5. Schecter AL, Stern DF, Vaidyanathan L, Decker S, Drebin JA, Greene MI, et al. The neu oncogene: An erbB-related gene encoding a 185,000-Mr tumor antigen. Nature 1984;312:513-6.
6. Slamon DJ, Goldolphin W, Jones LA, Holt GA, Wong SG, Keith DE, et al. Studies of the HER-2/proto-oncogene in human breast cancer and ovarian cancer. Science 1989;244:707-12.
7. Results of Iraqi cancer registry 1997-2002: Iraqi Cancer Board, Iraqi Cancer Registry Ministry of Health, Baghdad Iraq.
8. Al-Azzawi SN. Depleted uranium radioactive contamination In Iraq: An overview. Global Research. Vol. 1. August 31, 2006. p. 4.
9. Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, et al. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003,98:1587-95.
10. Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002;3:125-35.
11. Dowsett M, Bartlett JM, Ellis IO, Salter J, Hills M, Mallon E, et al. Correlation between Immunohistochemistry (Hercep Test) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centers. J Pathol 2003;199:418-23.
12. Selim AG, El-Ayat G, Wells GA. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Virchows Arch 2002;441:449-55. (Pubitemid 35430459)
13. Van DE, Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, et al. Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
14. Saleh F, Abdeen S. Pathobiological features of breast tumours in the State of Kuwait: A comprehensive analysis. J Carcinog 2007;6:12.
15. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-56.
16. Al-Moundhri M, Nirmala V, Al-Mawaly K, Ganguly S, Burney I, Rizvi A, et al. Significance of P53, Bcl2 and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res 2003;9:226-31.
17. Lan C, Ming Liu J, Liu TW, Hsu DH, Shuching L, Chen JR, et al. Erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+in immunohistochemical analysis. Am J Clin Pathol 2005;124:97-102.
18. Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, et al. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers and Prev 2000,9:65-71. (Pubitemid 30062911)
19. Czerniecki BJ, Roses RE, Kosi GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res 2007,67:6531-4.